Participants 289 361 7
in patients with chronic immune thrombocytopenia during a 6-month period
Participants 371 737 7
We undertook a phase 3, double-blind, placebo-controlled study in adults with previously treated immune thrombocytopenia of more than 6 months' duration who had baseline platelet counts lower than 30,000 per Î¼L. Patients were randomly allocated (in a 2:1 ratio) treatment with local standard of care plus 50 mg eltrombopag or matching placebo once daily for 6 month
Participants 1467 1564 6
INGS Between Nov 22, 2006, and July 31, 2007, 197 patients were randomly allocated to treatment g
Participants 2823 2929 5
penia, and could be particularly beneficial for patients who have not responded to splenectomy or previous
